FDA panel backs bladder cancer test:

Martitech, of Newton, Massachusetts, could soon be marketing its bladder cancer test for patients who have symptoms or are at risk of the disease, if the FDA takes the advice of its advisory panel. Last week, the panel recommended that the NMP22 test kit, which is already approved in the US for monitoring bladder cancer recurrence, should also be used on undiagnosed patients with symptoms or on those at high risk, providing there is an increase in the cut-off value and labelling that suggests it should be used with the current standard of care.